Dupilumab improves histologic outcomes of eosinophilic esophagitis: NEJM Jacinthlyn Sylvia28 Dec 2022 9:45 AM ISTA new study published in The New England Journal of Medicine suggests that subcutaneous dupilumab given weekly to individuals with eosinophilic...
Dupilumab effective against moderate-to-severe AD across all anatomic regions Dr. Shravani Dali23 Dec 2022 8:00 PM ISTIn adult patients with moderate-to-severe atopic dermatitis, treatment with dupilumab resulted in rapid and sustained improvement in the signs of...
Sanofi gets EMA panel recommendation for Dupixent to treat eosinophilic esophagitis Ruchika Sharma19 Dec 2022 10:30 AM ISTEoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
Sanofi Dupixent gets European Commission nod for Prurigo Nodularis Ruchika Sharma18 Dec 2022 5:30 PM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Commission (EC) has expanded the marketing authorization for...
Sanofi Dupixent recommended for EU approval by CHMP for prurigo nodularis treatment Ruchika Sharma13 Nov 2022 4:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
Serum Dupilumab levels fail to reveal treatment response in Atopic Dermatitis at 16 weeks Dr.Niharika Harsha B3 Nov 2022 8:00 PM ISTA new clinical study found that serum dupilumab levels do not affect treatment response and adverse effects during the first year of treatment at 16...
Dupilumab reduces exacerbations and improves FEV1 in uncontrolled, moderate-to-severe asthma Dr.Niharika Harsha B24 Oct 2022 8:00 PM ISTA recent study found that in patients having uncontrolled, moderate-to-severe asthma Dupilumab showed sustained, long-term reduction in exacerbations...
Dupilumab associated with "highly favorable" outcomes in Type 2 Chronic Rhinosinusitis Aditi6 Oct 2022 10:30 AM ISTSwitzerland: A recent study published in Allergy, European Journal of Allergy and Clinical Immunology, predicted treatment outcome as "highly...
FDA approves dupilumab as first and only treatment Indicated for Prurigo Nodularis Dr. Kamal Kant Kohli2 Oct 2022 7:30 PM ISTPrurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest...
Sanofi Prurigo nodularis drug Dupixent gets USFDA okay Ruchika Sharma30 Sept 2022 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Dupixent (dupilumab) for the treatment of adult patients...
Dupilumab significantly improves skin lesions and itching among treated patients with prurigo nodularis Dr. Kamal Kant Kohli21 Sept 2022 8:00 PM ISTDupilumab improves skin lesions and itching among treated patients with prurigo nodularis, reveals Initrial data presented at the European Academy of...
Sanofi, Regeneron Pharma announce positive Phase 3 data for Dupixent in adults with uncontrolled prurigo nodularis Ruchika Sharma10 Sept 2022 12:56 PM ISTPeople with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
